Researchers from UCSD, the Dana-Farber Cancer Institute, the
Mayo Clinic and TargeGen, a San Diego pharmaceutical company, have joined
together to perform human clinical trials of a new drug to treat a rare class
of blood diseases.
In one year, the partnership has moved from identifying the
appropriate drug candidate to performing clinical trials in order to fight a
number of Myeloproliferative disorders that are caused by the same genetic
mutation and can lead to leukemia. The degenerative blood disorder affects more
than 100,000 Americans.
The study was led by Catriona Jamieson, assistant professor
of medicine and director for stem cell research at the Rebecca and
and funded by the California Institute for Regenerative Medicine.
